News
Moon Shots Program
Since starting the Moon Shots Program® in 2012, we’ve made progress. And lots of it. Keep checking back here to stay up-to-date on the program’s achievements and see our latest innovations.
/cancermoonshots/about/news.html
According to results from a Phase I/IIa trial at The University of Texas MD Anderson Cancer Center, treatment with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK)-cell therapy targeting CD19 resulted in clinical responses in a majority of patients with relapsed or refractory non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL), with no major toxicities observed.
The trial results were...
HOUSTON ― A new discovery from researchers at The University of Texas MD Anderson Cancer Center has clarified the long-established connection...
Researchers from The University of Texas MD Anderson Cancer Center have discovered that grouping epidermal growth factor receptor (EGFR) mutations...
The University of Texas MD Anderson Cancer Center and SNIPR BIOME today announced a strategic collaboration to advance new CRISPR-based microbiome...
The University of Texas MD Anderson Cancer Center and Blueprint Medicines Corporation today announced a three-year strategic research collaboration...